The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial
^{Chughtai B, Elterman D, Shore N et al. Urology. 2021;153:270-276.}
Objective
To compare treatment results with the iTindprocedure vs. sham treatment in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).

Results

• A total of 175 men (mean age 61.1 ±6.5 years) participated in the study (118 iTind procedure vs 57 sham).
• At 3 months, 78.6% of the iTind procedure patients had a ≥3-point reduction in the International Prostate Symptom Score (IPSS), vs. 60% in the sham group (P= 0.029). After 3 months, the sham group was unblinded, and the study primarily focused on the iTind procedure group for long-term outcomes.
• Ninety seven percent of the iTind procedure patients that responded to treatment at 3 months maintained their response at 12 months.
• Mild adverse events (AEs) occurred in 38.1% of the iTind procedure patients and 17.5% of sham patients. Node novo ejaculatory or erectile dysfunction reported.

Conclusion
The iTind procedure provides significant, rapid, and durable improvement in LUTS due to BPH and preserves sexual function over a follow-up period of 12 months.

> Read full study
> Download study summary (PDF, 152 KB)

Temporary implantable nitinol device for benign prostatic hyperplasia-related lower urinary tract symptoms: over 48-month results
^{AmparoreD, De Cillis S, Schulman C et al. Minerva UrolNephrol. 2023;75(6):743-751.}
Objective
To assess through over 48-month (50–79 months) outcomes of the iTindprocedure in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) in a prospective, single-arm, multicenter, international study.

Results

• A total of 81 men were enrolled; 41 patients remained past 48 months. Due to COVID-19, in-person visits were replaced with a single phone evaluation at 50–79 months post-operation. Data were grouped under a single timepoint “over 48 months”.
• The iTindprocedure significantly improved symptoms (intention-to-treat analysis), with Quality of Life (QoL) increasing by 45.1% (P< 0.0001) from baseline to over 48 months post-procedure.
• No complications or additional medication needed from 48 to 79 months.
• Surgical re-treatment rate was 4% beyond 48 months.

Conclusion
The iTind procedure provided significant and long-lasting symptom relief, as well as improved quality of life for up to and beyond 48 months, with no late-stage complications.

> Read full study
> Download study summary (PDF, 179 KB)

Urinary and sexual function after treatment with temporary implantable nitinol device (iTind) in men with LUTS: 6-month interim results of the MT-06-study
^{De Nunzio C, Cantiello F, Fiori C et al. World J Urol. 2021;39(6):2037-2042.}
Objective
To evaluate functional outcome and preservation of urinary continence and sexual function in men treated with the iTindprocedure for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).

Results

• Seventy patients with a median age of 62.3 years and a mean prostate volume of 37.7 ml (15–80 ml) were enrolled.
• Compared to baseline, all parameters showed significant improvements (P< 0.01):
  • IPSS decreased from 21.2 ±6.0 to 8.3 ±6.7.
  • QoL score improved from 4.1 ±1.0 to 2.0 ±1.4.
  • Qmaxincreased from 7.3 ±2.2 to 12.0 ±5.4.
• All patients showed preserved sexual function and urinary continence according to ISI, SHIM and MSHQ-EjDquestionnaires.
• No intraoperative complications were observed; average post-operative VAS score was 3.2 ±2.6.

Conclusion
Treatment with the iTindprocedure preserves urinary continence and sexual function, offers rapid recovery, and provides significant improvements in LUTS and urinary flow at 6-month follow-up.

> Read full study
> Download study summary (PDF, 157 KB)

Twenty-four months failure rate and functional outcomes comparison after implantable nitinol device (iTIND) and prostatic urethral lift (Urolift): real world multicenter study
^{Olivero A, De Cillis S, Amparore D et al. Urologia Journal. Published online December 27, 2025.}
Objective
To compare two minimally invasive treatments for male lower urinary tract symptoms, iTind and UroLift, by evaluating their 2-year functional outcomes and rates of treatment failure.

Results

• A total of 134 patients were included: (iTind 92 (68.7%), 42 (31.3%) UroLift). Baseline characteristics were overall comparable; however, UroLift patients were significantly younger (P= 0.006), had larger prostates (P< 0.001), and more frequent median lobe enlargement (P< 0.001).
• At 24 months, both treatments showed similar improvements on uroflowmetry parameters and symptom scores, with a corresponding reduction in PVR volume.
• Retreatment rates were comparable between groups (13.0% vs 11.9%, P= 0.8). UroLift was associated with a significantly higher rate of same-day discharge (71.4% vs 48.9%, P< 0.001).
• There were no significant differences in terms of intraoperative and postoperative complications between the two groups. Ejaculatory function was preserved in all patients.

Conclusion
At two years, iTind and UroLift demonstrated comparable failure rates and similar objective urinary outcomes. UroLift offered the advantage of reduced hospitalization, whereas iTind achieved greater symptom relief. The clinical relevance of this difference requires further investigation.

> Read full study
> Download study summary (PDF, 206 KB)

First Multi-Center, Real-World Study on the Temporary Implantable Nitinol Device (iTIND) for the Management of Lower Urinary Tract Symptoms Related to Benign Prostatic Obstruction
^{Castellucci R, Secco S, Olivero A et al. Société Internationale d'Urologie Journal. 2025;6(4):54 (Open Access).}
Objective
To evaluate the real-world outcomes at 12 months of the Temporary Implantable Nitinol Device (iTind) for the management of lower urinary tract symptoms (LUTS) caused by benign prostatic obstruction (BPO) in a retrospective, single-arm, multicenter study design.

Results

• Study included 74 patients that underwent successful iTinddevice implantation under local anesthesia or conscious sedation, with same-day discharge. Median operative time was 10 min.
• Median patient age was 52 years (IQR: 46-59) with median prostate volume of 30 mL (IQR: 26-38).
• From baseline to 12 months, Qmaxincreased from 9.0 mL/s (IQR: 7.6-11.0) to 13.4 mL/s (IQR: 11.6-16.8, P= 0.126), and IPSS-QoL improved from 4 points (IQR: 4-5) to 2 points (IQR: 1-3, P< 0.001).
• No intraoperative complications occurred; 6 patients experience non-serious postoperative complications. Surgical retreatment rate was 5.4% (4/74).
• Sexual and ejaculatory functions were fully preserved.*

Conclusion
The iTind procedure is a safe and effective option that improves urinary symptoms and quality of life preserving sexual and ejaculatory functions. It serves as a cost-effective “bridge treatment” that allows men to defer more invasive surgery, preserve future options, and as a first-line, achieve rapid relief without long-term side effects.

> Read full study
> Download study summary (, 1 KB)

I-Tind for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Mid-term outcomes from a multicenter cohort
^{Dimitri M, Calarco A, Filippi B et al. Urologia. 2025;0(0). Online ahead of print.}
Objective
To assess the safety, efficacy, and functional outcomes of the iTindprocedure over a 12-month period in men with symptomatic benign prostatic hyperplasia (BPH) unresponsive to alpha-blocker therapy, in a retrospective, single-arm, multicenter study design.

Results

• Study included 120 patients that underwent successful iTinddevice implantation; all were discharged the same day. The mean patient age was 52.9 (±7.9) years, and the average prostate volume was 40.5 mL (±12.25).
• From baseline to 12 months, Qmaxincreased from 7.6 ±2.6 to 15.7 ±7.1 mL/s (P< 0.001), and PVR decreased from 72.3 ±35.2 to 62.5 ±15.9 mL (P< 0.0001).
• All implants were retrieved after 6.1 ±0.9 days; three cases of incomplete closure were reported, and one was linked to a fibrous adenoma.
• Sexual and ejaculatory functions were fully preserved.*
• Durability and patient selection need long-term study confirmation.

Conclusion
The study results confirm that temporary implantation of the iTinddevice is a safe and effective solution for alleviating BPH symptoms, with lasting benefits seen at 12 months. Additionally, sexual and ejaculatory functions were fully preserved.

> Read full study
> Download study summary (PDF, 192 KB)

One-Year Outcomes of a UK Center Delivering Minimally Invasive Surgery for Bladder Outflow Obstruction Using Local Anesthetic Without Sedation in the Office Setting
^{Khadhouri S, Turnbull M, Drummond L et al. Journal of Endourology. 2025;39(11):1189-1194.}
Objective
To assess whether minimally invasive surgical therapies (MISTs) like iTind, Rezum, and UroLift can be effectively and safely performed for bladder outflow obstruction (BOO) using only local anesthesia, without sedation, in an outpatient clinic.

Results

• A total of 81 procedures were completed: Rezum (46.9%), UroLift (27.2%), and iTind (25.9%). The median patient age was 68 years which was similar across groups (interquartile range 63 – 74).
• During the procedure the mean patient pain visual analogue score (VAS) was 4.3 ± 2.8 out of 10 across all procedures, indicating good tolerability. The immediate complication rate was 11.1%, all below Clavien-Dindo grade III.
• At 3-month follow-up the International Prostate Symptom Score (IPSS) decreased to 11.3 ± 7.1 (44.1% reduction, P < 0.01); Quality of Life (QOL) improved to 2.4 ± 1.5 (47.8% reduction, P < 0.01); Maximum Urinary Flow Rate (Qmax) increased to 13.1 ± 5.5 mL/s (22.4% improvement, P < 0.01).

Conclusion
Performing MIST procedures for BOO under local anesthesia alone, without sedation, in an outpatient setting is both feasible and well-tolerated. The approach yields significant improvements in urinary symptoms and flow rates, with low complication rates. This model can reduce inpatient demand and optimize urological service delivery.

> Read full study
> Download study summary (PDF, 161 KB)